Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04617015 · ClinicalTrials.gov registry record · Early Phase 1
Defining and Treating Depression-related Asthma
A Early Phase 1 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
NCT04617015 is a Early Phase 1 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 39 participants.
The verdict
NCT04617015, a Early Phase 1 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma. This study will investigate whether children with depression and asthma have less allergic disease and less inflammation than children with asthma who do not have symptoms of depression. The study will also investigate whether the lungs of children with depression and asthma respond to an anticholinergic inhaler called ipratropium more than the lungs of non-depressed asthmatic children.
Interventions
- DRUG Ipratropium Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-09-09 |
| Est. Completion | 2019-03-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04617015
The ClinicalTrials.gov registry entry for NCT04617015 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ipratropium Bromide is the first listed.
NCT04617015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04617015 about?
NCT04617015 is a clinical study titled "Defining and Treating Depression-related Asthma". Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma. This study will investigate whether children with depression and asthma have less allergic disease and less inflammation than children with asthma who do not have symptoms of depressio...
What is the current status of trial NCT04617015?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2016-09-09. Estimated completion is 2019-03-11.
What interventions are being tested in trial NCT04617015?
The interventions under investigation include: Ipratropium Bromide (DRUG).
Who is sponsoring clinical trial NCT04617015?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.